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Abstract
Study objective: To assess changes in treatment of uncomplicated urinary tract infections (UTIs)
following implementation of recommendations based on national guidelines and local resistance
rates.
Methods: This pre- and post-intervention study included patients discharged home from the
Emergency Department (ED) with an uncomplicated UTI at a 439-bed teaching hospital. ED
prescribers were educated on how local antimicrobial resistance rates impact UTI practice
guidelines. Empiric treatment according to recommendations was assessed as the primary
outcome. Agreement between chosen therapy and isolated pathogen susceptibility was compared
before and after education. Reevaluation in the ED or hospital admission within 30 days for a
UTI was also evaluated.
Results: A total of 350 patients were studied (174 before and 176 after education). Of those, 255
had cystitis and 95 had pyelonephritis. Following education, choice of therapy consistent with
recommendations increased from 44.8% to 83% (difference 38.2%, 95% CI 33% to 43%;
P<0.001). The change was predominately driven by an increase in nitrofurantoin use for cystitis
from 12% to 80% (difference 68%, 95% CI 62% to 73%; P<0.001). Agreement between empiric
treatment and the isolated pathogen susceptibility improved for cystitis 74% to 89% (P=0.05),
and no change occurred in 30-day repeat ED visits for a UTI.
Conclusions: After implementation of treatment recommendations for uncomplicated UTIs
based on local resistance, empiric antibiotic selection improved in the ED. To further meet goals
of antimicrobial stewardship, additional interventions are needed.

1. Introduction
1.1 Background
The Infectious Diseases Society of America (IDSA) and the European Society for
Microbiology and Infectious Diseases published updated practice guidelines for uncomplicated
cystitis and pyelonephritis in women during 2011 [1]. Due to the large variance in Escherichia
coli resistance to fluoroquinolones and trimethoprim-sulfamethoxazole (TMP-SMX) throughout
the world, the guidelines place a large emphasis on the importance of using local resistance rates
to determine the best empiric treatment [1, 2]. Specifically, the guidelines recommend that TMPSMX no longer be used as first-line therapy for uncomplicated cystitis when local resistance for
E. coli exceeds 20%. If patients are being discharged on oral therapy for pyelonephritis in areas
where E. coli resistance to fluoroquinolones exceeds 10%, then it is also suggested that a onetime dose of a long-acting parenteral agent from a different antimicrobial class be used. Another
addition to the guidelines is the concept of avoiding collateral damage, which includes the
ecological adverse effects from antibiotic therapy, especially the selection of multi-drug resistant
organisms such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant
Enterococci and Clostridium difficile [1, 3]. It emphasized that drugs with minimal impact on the
microbiota, such as nitrofurantoin, should be utilized when possible while higher risk drugs,
including fluoroquinolones, should be reserved for infections more severe than cystitis [1].
The public health threat of antimicrobial resistance and the need to prevent its spread is at
the forefront of importance as demonstrated by the White House releasing an Executive Order
and National Strategy to Combat Antibiotic-Resistant Bacteria in September 2014 [4]. The need
for increased education on antimicrobial resistance and selection of therapy was demonstrated in
a recent survey of healthcare providers that revealed antibiotic resistance was not commonly

considered when prescribing antimicrobials despite the widespread concern for resistance [5].
The definition of antimicrobial stewardship according to guidelines from IDSA and the Society
of Healthcare Epidemiology of America is “to optimize clinical outcomes while minimizing
unintended consequences of antimicrobial use, including toxicity, the selection of pathogenic
organisms (such as Clostridium difficile), and the emergence of resistance” [6]. Antimicrobial
stewardship programs have successfully demonstrated the ability to safely reduce resistance by
emphasizing use of narrow-spectrum antimicrobials, but these efforts have largely focused on
inpatient settings despite the majority of prescribing for antibiotics occurring in outpatients. A
call to action has been expressed for antimicrobial stewardship in the ED as this clinical setting
can impact antibiotic use in both inpatients and outpatients [7]. Literature regarding
antimicrobial stewardship in the ED has been minimal, possibly due to the difficulties of
implementation in this setting. Some of these challenges include rapid patient turnover, the
diverse needs of those destined for either inpatient or outpatient care, a varied mix of providers,
and high staff turnover. A few of the inter-professional antimicrobial stewardship processes that
have led to positive patient outcomes in the ED include development of ED-specific
antibiograms as well as post-prescription culture follow-up [7-9]. The educational intervention in
this study was designed to assist prescribers in making the best choice of therapy for
uncomplicated UTIs, the infectious disease requiring the most frequent culture review.
1.2 Goals of This Investigation
The purpose of this study was to assess changes in treatment of uncomplicated UTIs
following implementation of recommendations derived from applying local antimicrobial
resistance patterns to national practice guidelines. It is hypothesized that increasing adherence to

the guidelines will result in a higher rate of isolated pathogens being susceptible to the prescribed
therapy.
2. Methods
2.1 Study Design and Setting
This was a quasi-experimental study comparing two separate time periods before and
after an educational intervention in November 2013. It was conducted at a 439-bed tertiary-care
teaching center with more than 57,000 ED visits annually and approximately 100 visits per
month for the diagnosis of any UTI. The facility has had an antimicrobial stewardship service
since 2011, but no previous attempts have been made to implement outpatient interventions.
Clinical pharmacists are present in the ED 24 hours each day. They verify patient medication
orders during their stay but do not evaluate outpatient prescriptions unless requested. A postprescription review program is in place to follow-up with patients who have positive culture
results after discharge. Outcome measures were compared for the months following November
2012 and November 2013. The institutional review board approved the study prior to beginning
research and provided a waiver of the requirement for informed consent as the intervention was
deemed to be of minimal risk to subjects.
2.2 Selection of Participants
Patients evaluated for a UTI by any ED provider during the specified time periods were
eligible for the study. This included exams by resident physicians, mid-level practitioners, and
attending physicians. Patients were identified through ED visit reports by diagnosis and were
included if they were female, 12-70 years old, discharged home from the ED with an
uncomplicated UTI, and received an antibiotic prescription. Exclusion criteria included patients

who were admitted for inpatient treatment, pregnant, catheterized, or diagnosed with a
complicated UTI for any other reason.
2.3 Interventions
With the help of the microbiology laboratory, an ED-specific antibiogram was
constructed to determine the rate of E. coli resistance to TMP-SMX, ciprofloxacin,
nitrofurantoin, and cefazolin locally. For outpatients, the antibiogram revealed susceptibilities for
these drugs of 75%, 80%, 99%, and 96% respectively. Based on this and the IDSA guidelines,
institution-specific recommendations were developed for the empiric treatment of uncomplicated
UTIs in the ED as shown in table 1.
After being endorsed by our local antimicrobial stewardship committee, institutionspecific recommendations were implemented through education by a pharmacist in the ED and
to resident physicians during their monthly meeting. In addition, all ED providers were
delivered education by email from the medical director of the ED reinforcing the
recommendations and their justification. Pharmacists did not actively review outpatient
prescriptions during the study. A preliminary audit of empiric prescribing was performed two
months into the post-education study period and then feedback on results was provided by email
to all ED providers as a reminder of the recommendations. The remaining patient charts were
reviewed at the end of the study period.
2.4 Methods and Measurements
All data were extracted systematically from the electronic medical record by one trained
investigator using a standardized data collection form with definitions of each variable.
Diagnosis of UTI was based on provider documentation and the ICD-9-CM codes assigned to the
visit. If the type of UTI was not specified, classification was based on evidence-based definitions

[10]. Patients were determined to have cystitis if there was no documentation of flank pain, fever,
leukocytosis (WBC ≥12,000/ml), or the prescriber recorded that there was no evidence for
pyelonephritis. An infection was defined as uncomplicated if it occurred in non-pregnant woman
with no known urological abnormalities. If documentation was not clear, the abstractor reviewed
the available data with the senior investigator. If there was a discrepancy, then a third
investigator was consulted for interpretation. The study team met regularly to review progress.
The drug, dose, frequency, duration and use of one-time parenteral injection, if warranted, were
assessed according to the recommendations in Table 1. After nitrofurantoin and cephalexin, the
use of TMP-SMX was considered appropriate in patients’ with a creatinine clearance (CrCl) 1560 ml/min and a beta-lactam allergy. The fluoroquinolones, ciprofloxacin and levofloxacin,
were appropriate in those with CrCl less than 60ml/min and a contraindication to both a betalactam and sulfa drug. These fluoroquinolones, TMP-SMX, or cephalosporins were considered
appropriate therapy in pyelonephritis in that order. Isolated pathogen susceptibilities were
compared to empiric therapy, and reevaluation for a UTI in the ED or hospital admission within
30 days was assessed to determine treatment failure.
2.5 Outcomes
The primary outcome of this study was to assess adherence to recommendations for the
treatment of uncomplicated UTIs based on local resistance rates. Secondary outcomes included
the agreement between empiric antibiotics prescribed and isolated pathogen susceptibilities, and
reevaluation in the ED or hospital admission for a UTI within 30 days.
2.6 Analysis
Primary and secondary outcomes were analyzed statistically according to data type.
Nominal data was assessed with Chi-square tests using GraphPad Prism version 5.00 for

Windows (GraphPad Software, San Diego California USA www.Graphpad.com). Continuous
data was analyzed with a Student’s t-test performed utilizing Microsoft Excel 2010 (Microsoft,
Redmond Washington USA). For the primary outcome, a sample size of 343 patients was
determined necessary to detect a 15% difference with an 80% power. A p-value of 0.05 was
considered statistically significant.
3. Results
3.1 Characteristics of Study Subjects
The flowchart of patients evaluated in the study is shown in Figure 1. The most common
diagnosis code was for “Nonspecific UTI.” Upon review, 255 patients were classified as having
cystitis and 95 with pyelonephritis. There were no meaningful differences in the demographics of
patients before and after education. Baseline characteristics are shown in Table 2. E. coli was
the most common pathogen in positive urine cultures for both pre-and post-education patients
with cystitis (73% and 71%, P=0.75), and pyelonephritis (75% and 58%, P=0.23), respectively.
3.2 Main Results
Antibiotics prescribed at discharge changed significantly following education (table 3).
Before the intervention, the choice of empiric therapy was consistent with recommendations
44.8% of the time compared to 83% after (difference 38.2%, 95% CI 33% to 43%; P<0.001).
This change was driven by significant decreases in TMP-SMX and fluoroquinolone use for
cystitis balanced with increases in prescribing of nitrofurantoin for cystitis and fluoroquinolones
for pyelonephritis. Overall prescribing according to institution-specific recommendations for the
treatment of UTIs in regard to antibiotic choice, dose, frequency, duration, and a 1-time
parenteral antibiotic dose for pyelonephritis pre- and post-education increased from 2.3% to 20%
(difference 17.7%, 95% CI 14% to 22%; P<0.001) (table 4). The lowest rate of adherence to
recommendations was in duration of therapy which changed from 16 % to 25.5 % (difference

9.5%, 95% CI 6% to 13%; P=0.029) and administration of a long-acting parenteral agent for
pyelonephritis different from the treatment at discharge. There was no further change in
prescribing observed after feedback was delivered via e-mail to providers following the initial
audit of empiric treatment halfway through the prospective study period.
When a urine culture was performed, the prescribed antibiotic was susceptible to the
isolated pathogen more often in cystitis following education (74% vs. 89%, P=0.05), but not in
pyelonephritis patients (90% vs. 76%, P=0.23). The rate of patients seeking follow-up care for a
UTI at the institution within 30 days was unchanged at 4.6% compared to 7.4% (P=0.27).
4. Discussion
We observed that the prescribing habits for treatment of uncomplicated UTIs changed to
utilize narrower-spectrum antibiotics after implementation of antimicrobial stewardship
recommendations in the ED. This is noteworthy because national guidelines were tied to local
resistance rates and providers adjusted empiric prescribing accordingly following education.
Since hospital pharmacists do not normally view the prescriptions patients are being discharged
home on, and community pharmacists do not have access to the medical record, no other
intervention was performed during the study period unless a provider asked for assistance. Our
results demonstrated the largest differences before and after education in treatment for patients
with cystitis, which is a very common diagnosis in emergency department patients being
discharged home. Although we were able to show significant improvements in appropriate
antibiotic choice, the results indicate further work can be done to optimize treatment.
Recently, outcomes have been published from another center replicating our
improvement in guideline adherence for the treatment of uncomplicated UTIs, in their case
through the utilization of an electronic order set. That intervention resulted in a 38% increase in
adherence to guidelines, primarily from a reduction similar to ours in use of fluoroquinolones for

cystitis. In that study, unnecessary antibiotic days were decreased from 250 to 52 per 200
patients [11]. Although our education improved the days of therapy prescribed to be more
consistent with guidelines, recommendations for treatment duration were only followed a
minority of the time. This may have been because our education focused primarily on attributing
rising resistance rates to empiric antibiotic selection as opposed to prolonged duration of therapy.
This leads us to believe that future studies intending to improve antibiotic use should also
incorporate utilization of order sets, custom-built with recommended agents based on local
resistance and durations of therapy. At our institution, order sets have been difficult to
implement during a time of transition between paper and electronic prescriptions so treatment
recommendations were distributed through verbal education with paper handouts provided and email. Although order sets were not included in this study, they will be considered for
antimicrobial stewardship efforts in the future based on the success of this baseline study.
One of the alarming findings from our experience was that patients labeled as having
pyelonephritis were being prescribed nitrofurantoin at discharge both before and after education.
This is concerning because nitrofurantoin does not achieve adequate concentrations in the kidney
tissue and is not appropriate to treat a potentially systemic infection. Although the retrospective
nature of this analysis could have misclassified the infection, it is a point that necessitates further
education to providers for the sake of patient safety. We have continued the practice of educating
ED providers on UTI treatment recommendations upon the annual arrival of new medical
residents.
The most commonly described antimicrobial stewardship intervention in the ED is postprescription culture review, and there have previously been improvements in readmission rates
for patients with this follow-up. One way pharmacists have assisted with these review programs

is to ensure that patients with positive test results are being treated appropriately after they have
left the ED [9, 12, and 13]. Our intervention was intended to improve prescribing before the
patient was discharged from the ED; subsequently leading to less follow-up that would be
needed later. In our experience, there was a clinically relevant improvement in the number of
times the isolated pathogen was susceptible to the prescribed antibiotic. We did not specifically
evaluate the number of minutes spent on post-prescription review in this study but felt there was
a meaningful decrease in the amount of follow-up needed for uncomplicated UTIs after the
intervention because the therapy chosen was active against the isolated pathogen more often.
This is especially important in an era of emphasis on cost-effective healthcare and limited
reimbursement for treatment failures. Our findings did not show a difference in the number of
reevaluations within 30-days between the two groups. This is most likely due to the fact that
even in the pre-education group, culture follow-up was being performed and patients were
contacted immediately if the organism was resistant to empiric treatment. They were then
changed to appropriate treatment based on the urine culture and susceptibility report. In the
meantime, even cystitis with organisms resistant to the prescribed therapy can sometimes be
alleviated due to the high concentrations of most antibiotics in the urine. This would potentially
limit the return of patients, even though it is not a reliable way to practice.
5. Limitations
This was a single center observational experience without randomization.
Recommendations were based on resistance rates that will differ in other geographic areas which
limits external validity. Our study spanned four to five months, one year apart, and this is not
long enough to determine whether cumulative resistance rates would change over time based on
the improved adherence to guidelines. Only uncomplicated UTIs were analyzed for this study

and the number of patients with a diagnosis of pyelonephritis was small, especially in the posteducation group, further limiting the applicability of results. The low number of pyelonephritis
cases in both groups may have been due to the definition chosen, as few patients had a fever
recorded. The majority of coding was for “non-specific UTIs”, and therefore, classification was
based on chart documentation. Despite patients being enrolled prospectively in the second half
of the study, all the charts were analyzed retrospectively and the authors had to apply definitions
for pyelonephritis and cystitis themselves. The abstractor was not blinded to study group because
of the nature of a before and after trial design. This leaves open the possibility that some patients
may have been misclassified, even though every effort was made to accurately assess these
patients without bias. Additionally, the report generated to identify patients evaluated for UTIs in
the ED changed slightly from the pre- to post-education group. The pre-education report was
able to identify all ICD-9 codes during the visit while the post-education report only identified
patients by the primary diagnosis. This could have contributed to the discrepancy in the number
of patients with pyelonephritis between the groups, although it seems unlikely that many patients
would be discharged with pyelonephritis as a secondary diagnosis in our experience. Finally,
there remains the possibility that patients initially evaluated in the ED could have sought followup care for their UTI at another site. This would lower our estimation of treatment failures both
before and after the intervention. Furthermore, the study was powered to show a difference in
treatment of 15%, but not reevaluation rates of 5%, so a larger trial would need to be conducted
to detect if any difference existed in that outcome.
6. Conclusion
In summary, outpatient prescribing in the ED changed significantly after implementation
of treatment recommendations for uncomplicated UTIs based on local resistance patterns and

national practice guidelines. This resulted in achieving a goal of antimicrobial stewardship by
decreasing use of broad spectrum agents for cystitis, specifically fluoroquinolones, and reserving
them for more severe infections. Subsequently, there was an increase in isolated pathogens
being susceptible to empiric therapy for cystitis following education. Additional studies of
antimicrobial stewardship in the emergency department are needed to determine the impact
interventions have on long-term resistance patterns, time required for post-prescription follow-up
and patient outcomes. In the future, we advise implementing order sets focusing on
recommended treatments including durations of therapy for urinary tract infections and
appropriate use of one-time doses for long-acting parenteral agents prior to discharge with
pyelonephritis.
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Figure 1. Study flowchart
Patients discharged
from ED with UTI
N=475

Patients excluded with
complicated UTI
N=125
Pre-education: n=53
Post-education: n=72

Patients included
N=350

Pre-education
n=174

Cystitis
n=106

Pyelonephritis
n=68

Post-education
n=176

Cystitis
n=149

Pyelonephritis
n=27

Table 1. Empiric treatment recommendations for acute uncomplicated urinary tract
infections
Cystitis
 1st choices
o Nitrofurantoin monohydrate/macrocrystals 100 mg every 12 hours for 5 days
 Only for patients with CrCl >60 ml/min
-ORo Cephalexin 500 mg every 12 hours for 7 days
 2nd choice
o Trimethoprim-sulfamethoxazole 160/800 mg every 12 hours for 3 days
 Appropriate in patients with CrCl <60 ml/min and a beta-lactam allergy
rd
 3 choice
o Ciprofloxacin 250 mg every 12 hours or levofloxacin 250 mg daily for 3 days
 Appropriate in patients with CrCl <60 ml/min plus a beta-lactam and sulfa
allergy
Pyelonephritis
 A urine culture and susceptibility should always be performed
 Give 1 dose of a long acting parenteral agent in the ED
o Ceftriaxone 1 g, gentamicin or tobramycin 5 mg/kg (Pharmacy to dose)
 Oral prescription for discharge
o 1st choice
 Ciprofloxacin 500 mg every 12 hours for 7 days or levofloxacin 750 mg daily
for 5 days
o 2nd choice
 Trimethoprim-sulfamethoxazole 160/800 mg every 12 hours for 14 days
o 3rd choice
 Cephalexin 500 mg every 6 hours for 14 days
Note: Doses are for patients with normal renal function. Adjustment of therapy may be required
for patients with kidney disease. CrCl = Creatinine clearance, ED = Emergency department.

Table 2. Patient characteristics
PreEducation
n=106

Cystitis
PostEducation
n=149

PreEducation
n=68

Pyelonephritis
PostEducation
n=27

P-value
P-value
Characteristic
Mean age,
31.8 (12.5) 29.5 (11.5)
0.14
34.4 (13.9)
32.1 (13)
0.47
years
Mean WBC,
9.5 (4.5)
8.9 (2.7)
0.44
10.7 (5.2)
12.3 (3.7)
0.19
k/mL
Mean
temperature,
36.7 (0.4) 36.8 (0.4)
0.48
36.9 (0.6)
36.9 (0.5)
0.84
℃
Mean SCr
0.80 (0.2) 0.84 (0.1)
0.15
0.83 (0.2)
0.80 (0.1)
0.57
Mean CrCl
88.5 (12.7) 98 (26.2)
0.04
87.2 (17.3)
99.3 (25.7)
0.03
Urine culture
58 (54.7) 103 (69.1)
0.02¥
54 (79.4)
22 (81.5)
0.82¥
performed (%)
Mean days of
7 (2.8)
7.2 (2.2)
0.46
7.9 (2.9)
8.4 (2.8)
0.43
treatment
All values are number (±SD) unless specified. All p-values by Student’s t-test unless noted. ¥Chisquare test

Table 3. Antibiotics prescribed at discharge
Cystitis
Pyelonephritis
PrePostPrePostEducation education
P-value
Education
Education
n=106 (%) n=149 (%)
n=68 (%)
n=27 (%)
Cephalexin
1 (0.9)
2 (1.3)
0.77
0
1 (18.5)
FQs
35 (33)
16 (12.8)
<0.001
32 (47)
19 (70.4)
TMP-SMX
56 (52.8)
8 (5.4)
<0.001
29 (43)
2 (7.4)
Nitrofurantoin 13 (12.3) 119 (79.9)
<0.001
7(10)
5 (18.5)
Doxycycline
1 (0.9)
0
0.23
--FQs=fluoroquinolones: ciprofloxacin or levofloxacin, All p-values by Chi-square test.

P-value
0.11
0.04
0.001
0.28

Table 4. Results of adherence to recommendations
Pre-education
N=174 (%)
Combined cystitis and
4 (2.3)
pyelonephritis overall
Cystitis
n=106 (%)
Discharge antibiotic
17 (16)
Dose
87 (82)
Frequency
105 (99)
Duration
22 (20.8)
Overall adherence
3 (2.8)
Pyelonephritis
n=68 (%)
Parenteral antibiotic in
6 (8.8)
ED
Discharge antibiotic
61 (89.7)
Dose
55 (80.9)
Frequency
62 (91.2)
Duration
6 (8.8)
Overall adherence
1 (1.5)
ED = Emergency department, All p-values by Chi-square test.

Post-Education
N=176 (%)

P-value

35 (20)

<0.001

n=149 (%)
124 (83.2)
138 (92.6)
146 (97.9)
35 (23.2)
32 (21.5)
n=27 (%)

<0.001
0.02
0.64
0.65
<0.0001

3 (11.1)

0.73

22 (81.5)
22 (81.5)
22 (81.5)
10 (37)
3 (11)

0.28
0.95
0.18
<0.001
0.03

